60 related articles for article (PubMed ID: 31486207)
1. A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Brisson RJ; Kochanny S; Arshad S; Dekker A; DeSouza JA; Saloura V; Vokes EE; Seiwert TY
Head Neck; 2019 Nov; 41(11):3842-3849. PubMed ID: 31486207
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Garrido-Castro AC; Saura C; Barroso-Sousa R; Guo H; Ciruelos E; Bermejo B; Gavilá J; Serra V; Prat A; Paré L; Céliz P; Villagrasa P; Li Y; Savoie J; Xu Z; Arteaga CL; Krop IE; Solit DB; Mills GB; Cantley LC; Winer EP; Lin NU; Rodon J
Breast Cancer Res; 2020 Nov; 22(1):120. PubMed ID: 33138866
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Razak ARA; Wang HM; Chang JY; Ahn MJ; Munster P; Blumenschein G; Solomon B; Lim DW; Hong RL; Pfister D; Saba NF; Lee SH; van Herpen C; Quadt C; Bootle D; Blumenstein L; Demanse D; Delord JP
Target Oncol; 2023 Nov; 18(6):853-868. PubMed ID: 37875771
[TBL] [Abstract][Full Text] [Related]
4. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
van den Bent M; Azaro A; De Vos F; Sepulveda J; Yung WKA; Wen PY; Lassman AB; Joerger M; Tabatabai G; Rodon J; Tiedt R; Zhao S; Kirsilae T; Cheng Y; Vicente S; Balbin OA; Zhang H; Wick W
J Neurooncol; 2020 Jan; 146(1):79-89. PubMed ID: 31776899
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
McPherson V; Reardon B; Bhayankara A; Scott SN; Boyd ME; Garcia-Grossman IR; Regazzi AM; McCoy AS; Kim PH; Al-Ahmadie H; Ostrovnaya I; Roth AJ; Farooki A; Berger MF; Rosenberg JE; Solit DB; Van Allen E; Milowsky MI; Bajorin DF; Iyer G
Cancer; 2020 Oct; 126(20):4532-4544. PubMed ID: 32767682
[TBL] [Abstract][Full Text] [Related]
6. Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
McGowan DR; Skwarski M; Bradley KM; Campo L; Fenwick JD; Gleeson FV; Green M; Horne A; Maughan TS; McCole MG; Mohammed S; Muschel RJ; Ng SM; Panakis N; Prevo R; Strauss VY; Stuart R; Tacconi EMC; Vallis KA; McKenna WG; Macpherson RE; Higgins GS
Eur J Cancer; 2019 May; 113():87-95. PubMed ID: 30991262
[TBL] [Abstract][Full Text] [Related]
7. A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer.
Seo S; Keam B; Shin SH; Chae YS; Kim TM; Park LC; Hong SB; Ahn MJ; Kim SB
Int J Cancer; 2023 Oct; 153(8):1501-1511. PubMed ID: 37357950
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
Desilets A; Pfister DG; Stein S; Wong W; Sherman EJ; Fetten J; Hung TKW; Kriplani A; Dunn LA; Ho AL; Michel LS
Oral Oncol; 2024 May; 154():106861. PubMed ID: 38795600
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database.
Lu HJ; Hsieh MC; Wang HM; Hsieh JC; Yen CJ; Wu SY; Huang HC; Wang HC; Chu PY; Chen TH; Chien CY; Huang TL; Chang YF; Hua CH; Lien MY; Chen JP; Lu WC; Lin JC; Wang CC; Liu YC; Yang MH; Lou PJ
Head Neck; 2024 May; 46(5):1063-1073. PubMed ID: 38385970
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.
Rosenthal EL; Moore LS; Tipirneni K; de Boer E; Stevens TM; Hartman YE; Carroll WR; Zinn KR; Warram JM
Clin Cancer Res; 2017 Aug; 23(16):4744-4752. PubMed ID: 28446503
[No Abstract] [Full Text] [Related]
11. Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma.
Grommes C; Pentsova E; Schaff LR; Nolan CP; Kaley T; Reiner AS; Panageas KS; Mellinghoff IK
Leuk Lymphoma; 2023 Sep; 64(9):1545-1553. PubMed ID: 37317993
[TBL] [Abstract][Full Text] [Related]
12. Reply to 'The use of buparlisib as a radiosensitiser: What about toxicity?'.
McGowan DR; Skwarski M; Higgins GS
Eur J Cancer; 2019 Sep; 119():196-197. PubMed ID: 31427118
[No Abstract] [Full Text] [Related]
13. A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
Dunn LA; Riaz N; Fury MG; McBride SM; Michel L; Lee NY; Sherman EJ; Baxi SS; Haque SS; Katabi N; Wong RJ; Xiao H; Ho AL; Pfister DG
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):564-570. PubMed ID: 31678634
[TBL] [Abstract][Full Text] [Related]
14. EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.
Piper AK; Penney C; Holliday J; Tincknell G; Ma Y; Napaki S; Pantel K; Brungs D; Ranson M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791602
[TBL] [Abstract][Full Text] [Related]
15. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
Shan KS; Bonano-Rios A; Theik NWY; Hussein A; Blaya M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396649
[TBL] [Abstract][Full Text] [Related]
16. Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity.
Zaryouh H; De Pauw I; Baysal H; Melis J; Van den Bossche V; Hermans C; Lau HW; Lambrechts H; Merlin C; Corbet C; Peeters M; Vermorken JB; De Waele J; Lardon F; Wouters A
Cancer Drug Resist; 2023; 6(4):709-728. PubMed ID: 38239393
[No Abstract] [Full Text] [Related]
17. Targeted therapy for head and neck cancer: signaling pathways and clinical studies.
Li Q; Tie Y; Alu A; Ma X; Shi H
Signal Transduct Target Ther; 2023 Jan; 8(1):31. PubMed ID: 36646686
[TBL] [Abstract][Full Text] [Related]
18. Cancer Cell Metabolism Reprogramming and Its Potential Implications on Therapy in Squamous Cell Carcinoma of the Head and Neck: A Review.
Perri F; Della Vittoria Scarpati G; Pontone M; Marciano ML; Ottaiano A; Cascella M; Sabbatino F; Guida A; Santorsola M; Maiolino P; Cavalcanti E; Togo G; Ionna F; Caponigro F
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892820
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
Trigo J; García-Cosío M; García-Castaño A; Gomà M; Mesia-Nin R; Ruiz-Bravo E; Soria-Rivas A; Castillo P; Braña-García I; Alberola-Ferranti M
Clin Transl Oncol; 2022 Oct; 24(10):1890-1902. PubMed ID: 35739348
[TBL] [Abstract][Full Text] [Related]
20. Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine.
Ursu RG; Luchian I; Damian C; Porumb-Andrese E; Ghetu N; Cobzaru RG; Lunca C; Ripa C; Costin D; Jelihovschi I; Petrariu FD; Iancu LS
Diagnostics (Basel); 2022 Apr; 12(5):. PubMed ID: 35626227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
